Skip to content

Saffron trial finds no clear benefit for combined mood symptoms

In adults with subclinical symptoms, saffron did not significantly change the main depression, anxiety and fatigue outcome. A separate mental-health finding is difficult to interpret from the abstract.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Saffron did not show a statistically significant benefit for the combined symptom score or for depression, anxiety and fatigue considered individually. A separate self-rated mental-health result was described as improved, but the reported group means do not clearly support that interpretation. The primary null result does not prove that every possible effect is absent.

Keep in mind

The secondary mental-health claim is difficult to reconcile with the group means as labelled. Without the full analysis, the direction and meaning of that result remain uncertain.

THE RESULT, WITH CONTEXT

What researchers found

No statistically significant difference

Combined depression, anxiety and fatigue score

Saffron extract versus placebo after 6 weeks; the primary endpoint averaged standardized questionnaire scores. The abstract gives no effect estimate or confidence interval.

Am J Clin Nutr, 2025 · Original source ↓

The primary outcome

Researchers averaged standardized depression, anxiety and fatigue questionnaire scores for the main outcome. They also measured inflammatory markers and stress-system reactivity, neither of which showed a statistically significant response to saffron.

The secondary result needs clarification

The authors call for replication of the possible mental-health finding. That secondary result should be interpreted separately from the main symptom outcome, which did not show a statistically significant treatment effect.

CHECK THE ORIGINAL

The original publication

Effect of saffron extract supplementation on mood in healthy adults with subclinical symptoms of depression: a randomized, double-blind placebo-controlled study.

Amadieu C, Leyrolle Q, Farneti M et al.
Am J Clin Nutr · 2025

PubMed ID
41047129
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.